glp-1-rezeptoragonisten wohl auch bei Typ-1-Diabetes sinnvoll GLP-1-Rezeptor-Agonisten: Überraschende Anwendungsgebiete - FITBOOK

10.1016/j.molmet.2021.101428 226 ZhangL.WuX.YangR.ChenF.LiaoY.ZhuZ.et al (2021a)

607 In functional studies, astrocytes differentiated from stem cells obtained from familial AD showed aberrant Ca 2+ signalling, 608,609 increased production of reactive oxygen species, reduced lactate supply, compromised neuroprotection, and inability to support neurones in co-cultures

These groups received intravenous treatments of PBS, oridonin, orid-liposome, orid-liposome-MAL, TLR2 pep-orid-liposome at a dose of 5 mg/kg, or PBS as control every other day

The peptide backbone is a balanced GLP-1R/GIPR co-agonist (the MAR709 design lineage that became tirzepatide)

Together they address both visible and cellular markers of aging